• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 POS filed by Nu Skin Enterprises Inc.

    6/7/24 5:08:50 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care
    Get the next $NUS alert in real time by email
    S-8 POS 1 ef20030640_s8pos.htm FORM S-8 POS
    Registration No. 333-167690
    Registration No. 333-190508
    Registration No. 333-211617
    Registration No. 333-238908
     Registration No. 333-280044
    As filed with the Securities and Exchange Commission on June 7, 2024

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C.  20549


     
    POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S‑8 REGISTRATION STATEMENT NO. 333-167690
    POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S‑8 REGISTRATION STATEMENT NO. 333-190508
    POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S‑8 REGISTRATION STATEMENT NO. 333-211617
    POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S‑8 REGISTRATION STATEMENT NO. 333-238908
    POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S‑8 REGISTRATION STATEMENT NO. 333-280044

    UNDER
    THE SECURITIES ACT OF 1933



    NU SKIN ENTERPRISES, INC.
     
    (Exact name of registrant as specified in its charter)
     
    Delaware
    (State or other jurisdiction
    of incorporation or organization)
     
    87-0565309
    (I.R.S. Employer
    Identification No.)
     
    75 West Center Street
    Provo, Utah 84601
     
    (Address, including zip code,
    of registrant’s principal executive offices)
     


    Nu Skin Enterprises, Inc. 2010 Omnibus Incentive Plan
    Amended and Restated Nu Skin Enterprises, Inc. 2010 Omnibus Incentive Plan
    Second Amended and Restated Nu Skin Enterprises, Inc. 2010 Omnibus Incentive Plan
    Third Amended and Restated Nu Skin Enterprises, Inc. 2010 Omnibus Incentive Plan
    Nu Skin Enterprises, Inc. 2024 Omnibus Incentive Plan
    (Full title of the plans)
     

     
    Ryan S. Napierski
    President and Chief Executive Officer
    Nu Skin Enterprises, Inc.
    75 West Center Street
    Provo, Utah 84601
    (801) 345-1000
     
    (Name, address and telephone number,
     including area code, of agent for service)


     
    Copies to:
    Roger Bivans
    Baker & McKenzie LLP
    1900 North Pearl
    Suite 1500
    Dallas, TX 75201
    (214) 978-3095
     
    Chayce D. Clark
    Executive Vice President and General Counsel
    Nu Skin Enterprises, Inc.
    75 West Center Street
    Provo, Utah 84601
    (801) 345-1000


     
    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

    Large accelerated filer  ☑
    Accelerated filer  ☐
    Non-accelerated filer  ☐
    Smaller reporting company  ☐
     
    Emerging growth company  ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.  ☐


     


    EXPLANATORY NOTE
     
    Nu Skin Enterprises, Inc. (the “Registrant”), previously filed with the Securities and Exchange Commission (the “SEC”) the following registration statements on Form S-8 (collectively, the “Prior Registration Statements”) on the dates set forth below to register shares of the Registrant’s Class A Common Stock, $0.001 par value per share (the “Common Stock”):
     

    •
    Registration No. 333-167690 on June 23, 2010 to register 7,000,000 shares of Common Stock under the Registrant’s 2010 Omnibus Incentive Plan and its amendments (collectively, the “Prior Plan”)

    •
    Registration No. 333-190508 on August 9, 2013 to register 3,247,616 shares of Common Stock under the Prior Plan

    •
    Registration No. 333-211617 on May 25, 2016 to register 3,752,694 shares of Common Stock under the Prior Plan

    •
    Registration No. 333-238908 on June 3, 2020 to register 5,896,993 shares of Common Stock under the Prior Plan

    •
    Registration No. 333-280044 on June 7, 2024 to register 1,219,919 shares of Common Stock under the Registrant’s Nu Skin Enterprises, Inc. 2024 Omnibus Incentive Plan (the “2024 Plan”)
     
    The Registrant’s stockholders approved the 2024 Plan at the Registrant’s 2024 Annual Meeting of Stockholders on June 5, 2024 (the “Effective Date”), and accordingly, no further awards may be granted under the Prior Plan. Pursuant to the terms of the 2024 Plan, the number of shares of Common Stock reserved and available for grant and issuance pursuant to the 2024 Plan is equal to the sum of (i) 1,219,919 shares of Common Stock (the “Newly Authorized Shares”), plus (ii) the number of shares of Common Stock which as of the Effective Date are available for issuance under the Prior Plan (the “Rollover Shares”), plus (iii) the number of shares of Common Stock subject to outstanding awards granted under the Prior Plan that are therefore issuable under the 2024 Plan (the “Recycled Shares” and together with the “Rollover Shares,” the “Transferred Shares”).
     
    The Registrant is filing this Post-Effective Amendment No. 1 to the Prior Registration Statements (the “Post-Effective Amendment”) pursuant to Regulation S-K Item 512(a)(1)(iii) and SEC Compliance and Disclosure Interpretation 126.43 to amend each of the Prior Registration Statements to register the offer of the Transferred Shares under the 2024 Plan.
     
    In accordance with SEC Compliance and Disclosure Interpretation 126.43, no new filing fee is due upon the filing of this Post‑Effective Amendment. For the avoidance of doubt, the Registrant is not hereby registering any additional shares of Common Stock on this Post-Effective Amendment that were not previously registered on the Prior Registration Statement or that were not previously approved by the Registrant’s stockholders as of the Effective Date. Contemporaneously with the filing of this Post‑Effective Amendment, the Company is filing a Registration Statement on Form S-8 to register the Newly Authorized Shares under the Plan.
     
    1

    PART I
     
    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS
     
    The documents containing the information specified in Item 1 and Item 2 of Part I of Form S-8 will be sent or given to participants as specified by Rule 428(b)(1) under the Securities Act of 1933, as amended (the “Securities Act”). In accordance with the rules and regulations of the U.S. Securities and Exchange Commission (the “Commission”) and the instructions to Form S-8, such documents are not being filed with the Commission either as part of this Post-Effective Amendment or as prospectuses or prospectus supplements pursuant to Rule 424 under the Securities Act.
     
    PART II
     
    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
     
    Item 3.
    Incorporation of Documents by Reference.
     
    The following documents, which have been filed with the Securities and Exchange Commission (the “Commission”) by Nu Skin Enterprises, Inc. (the “Company”), are incorporated by reference in this Post-Effective Amendment, except to the extent that information therein is deemed furnished and not filed pursuant to securities laws and regulations:
     
      (a)
    the Company’s Annual Report on Form 10‑K for the fiscal year ended December 31, 2023;
     

    (b)
    the Company’s Quarterly Report on Form 10‑Q for the quarter ended March 31, 2024;
     

    (c)
    the Company’s Current Reports on Form 8-K filed on February 6, 2024, February 14, 2024, March 18, 2024 and June 6, 2024; and
     

    (d)
    the description of the Company’s Class A Common Stock, par value $0.001 per share, filed as Exhibit 4.2 to the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed on February 15, 2024, together with any amendment or report filed with the Commission for the purpose of updating such description.
     
    All documents filed by the Company pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), subsequent to the date hereof and prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all securities remaining unsold shall be deemed to be incorporated by reference herein and to be a part hereof from the respective dates of filing of such documents.
     
    Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Post-Effective Amendment to the extent that a statement contained herein or in any other subsequently filed document that also is, or is deemed to be, incorporated by reference herein modifies or supersedes such statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Post-Effective Amendment.
     
    Item 4.
    Description of Securities.
     
    Not applicable.
     
    Item 5.
    Interests of Named Experts and Counsel.
     
    Not applicable.
     
    Item 6.
    Indemnification of Directors and Officers.
     
    Indemnification
     
    The registrant is incorporated under the laws of the State of Delaware. Section 145 of the Delaware General Corporation Law (the “DGCL”) provides that a Delaware corporation may indemnify persons who were, are or are threatened to be made parties to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (other than an action by or in the right of such corporation), by reason of the fact that such person is or was a director, officer, employee or agent of such corporation, or is or was serving at the request of such corporation as a director, officer, employee or agent of another corporation or enterprise. The indemnity may include expenses (including attorneys’ fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by such person in connection with such action, suit or proceeding, provided such person acted in good faith and in a manner the person reasonably believed to be in or not opposed to the corporation’s best interests and, with respect to any criminal action or proceeding, had no reasonable cause to believe that his or her conduct was unlawful. The registrant’s certificate of incorporation and bylaws provide for the indemnification of the registrant’s officers and directors to the fullest extent permitted by the DGCL. The registrant believes that such indemnification is necessary to attract and retain qualified persons as directors and officers. The registrant has also entered into separate indemnification agreements with each of its directors and executive officers.
     
    2

    Liability Insurance
     
    Section 145 of the DGCL also permits a Delaware corporation to purchase and maintain insurance on behalf of its directors and officers. The registrant’s certificate of incorporation and bylaws permit the registrant to purchase such insurance on behalf of its directors and officers. The registrant believes that such insurance is necessary to attract and retain qualified persons as directors and officers. The registrant has purchased such insurance on behalf of its directors and officers.
     
    Limitation of Liability
     
    Section 102(b)(7) of the DGCL provides that the certificate of incorporation of a corporation may contain a provision eliminating or limiting the personal liability of a director or officer to the corporation or its stockholders for monetary damages for breach of fiduciary duty as a director or officer, provided that such provision shall not eliminate or limit the liability of: (i) a director or officer for any breach of the director’s or officer’s duty of loyalty to the corporation or its stockholders; (ii) a director or officer for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law; (iii) a director under Section 174 of the DGCL; (iv) a director or officer for any transaction from which the director or officer derived an improper personal benefit; and (v) an officer in any action by or in the right of the corporation. The registrant’s certificate of incorporation provides for, to the fullest extent permitted by the DGCL, elimination or limitation of liability of its directors to the registrant or its stockholders for breach of fiduciary duty as a director.
     
    Item 7.
    Exemption from Registration Claimed.
     
    Not applicable.
     
    Item 8.
    Exhibits.
     
    Unless otherwise noted, the SEC file number for exhibits incorporated by reference is 001-12421.
     
    Exhibit
    Number
     
    Description
    4.1
     
    Amended and Restated Certificate of Incorporation of the Company (incorporated by reference to Exhibit 3.1 to the Company’s Registration Statement on Form S-1 filed September 16, 1996, File No. 333-12073).
    4.2
     
    Certificate of Amendment to the Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.2 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2009, filed March 1, 2010).
    4.3
     
    Certificate of Designation, Preferences and Relative Participating, Optional and Other Special Rights of Preferred Stock and Qualifications, Limitations and Restrictions Thereof (incorporated by reference to Exhibit 3.3 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2004, filed March 15, 2005).
    4.4
     
    Fifth Amended and Restated Bylaws of Nu Skin Enterprises, Inc. (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed February 6, 2024).
    4.5
     
    Specimen Form of Stock Certificate for Class A Common Stock (incorporated by reference to Exhibit 4.1 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2022, filed February 16, 2023).
    23.1*
     
    Consent of PricewaterhouseCoopers LLP, independent registered public accounting firm.
    24.1*
     
    Power of Attorney (included on the signature page of this Post-Effective Amendment).
    99.1
     
    Nu Skin Enterprises, Inc. 2010 Omnibus Incentive Plan (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on June 2, 2010).
    99.2
     
    Amended and Restated Nu Skin Enterprises, Inc. 2010 Omnibus Incentive Plan (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on June 7, 2013).
    99.3
     
    Second Amended and Restated Nu Skin Enterprises, Inc. 2010 Omnibus Incentive Plan (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed May 24, 2016).
    99.4
     
    Third Amended and Restated 2010 Omnibus Incentive Plan (incorporated by reference to Exhibit 99.1 to the Company’s Registration Statement on Form S-8 filed June 3, 2020, file no. 333-238908).
    99.5
     
    Nu Skin Enterprises, Inc. 2024 Omnibus Incentive Plan (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed June 6, 2024).

    * Filed herewith.

    3

    Item 9.
    Undertakings.
     
    (a)          The undersigned registrant hereby undertakes:
     
    (1)          To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:
     
    (i)           To include any prospectus required by Section 10(a)(3) of the Securities Act of 1933;
     
    (ii)          To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement.  Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20% change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective registration statement; and
     
    (iii)         To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement;
     
    Provided, however, that paragraphs (a)(1)(i) and (a)(1)(ii) do not apply if the registration statement is on Form S-8, and the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in the registration statement.
     
    (2)         That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
     
    (3)          To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.
     
    (b)          The undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
     
    (c)          Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable.  In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.
     
    4

    SIGNATURES
     
    Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S‑8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Provo, State of Utah, on this 7th day of June, 2024.
     

    NU SKIN ENTERPRISES, INC.




    By /s/ Ryan S. Napierski


    Name:  Ryan S. Napierski


    Title:  President and Chief Executive Officer
     
    POWER OF ATTORNEY
     
    KNOW ALL MEN BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Ryan S. Napierski and Chayce D. Clark, and each of them, his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments to the registration statement (including post-effective amendments), and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting each of said attorneys-in-fact and agents full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as full to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents or any of them, or their substitute, may lawfully do or cause to be done by virtue hereof.
     
    Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities indicated and on the dates indicated.
     
    Signature
    Title
    Date
         
    /s/ Steven J. Lund
    Executive Chairman of the Board
    June 7, 2024
     Steven J. Lund    
         
    /s/ Ryan S. Napierski
    President, Chief Executive Officer and Director
    June 7, 2024
    Ryan S. Napierski
    (Principal Executive Officer)
     
         
    /s/ James D. Thomas
    Chief Financial Officer
    June 7, 2024
     James D. Thomas
    (Principal Financial Officer and Accounting Officer)
     
         
    /s/ Emma S. Battle
    Director
    June 7, 2024
    Emma S. Battle
       
         
    /s/ Daniel W. Campbell
    Director
    June 7, 2024
     Daniel W. Campbell    
         
    /s/ Laura Nathanson
    Director
    June 7, 2024
     Laura Nathanson    
         
    /s/ Thomas R. Pisano
    Director
    June 7, 2024
     Thomas R. Pisano    
         
    /s/ Zheqing Shen
    Director
    June 7, 2024
     Zheqing Shen    
         
    /s/ Edwina D. Woodbury
    Director
    June 7, 2024
     Edwina D. Woodbury    


    5

    Get the next $NUS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NUS

    DatePrice TargetRatingAnalyst
    1/31/2023$43.00 → $39.00Buy → Hold
    Jefferies
    2/17/2022$47.00 → $50.00Neutral
    DA Davidson
    11/24/2021$43.00 → $49.00Neutral
    Citigroup
    10/6/2021$61.00 → $47.00Neutral
    DA Davidson
    More analyst ratings

    $NUS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Dr. Joseph Chang Launches Update to Bestselling Book "The Aging Myth" With 15 More Years of Breakthrough Research on Cellular Wellness

    The updated edition of the New York Times bestseller from the chair of the Nu Skin Scientific Advisory Board reveals latest science behind measurable biology and evidence-based longevity Nu Skin Enterprises Inc. (NYSE:NUS) today announced the relaunch of "The Aging Myth: Unlocking the Mysteries of Looking and Feeling Young," the updated edition of the bestselling book from Dr. Joseph Chang, chair of Nu Skin's Scientific Advisory Board. The relaunch marks a significant milestone in the evolution of evidence-based beauty and wellness, bringing together decades of research that underpin Nu Skin's science-led innovations — from ageLOC® technology to the company's intelligent beauty and wellne

    2/6/26 1:56:00 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    Nu Skin Enterprises to Announce Fourth Quarter and Full Year 2025 Financial Results

    Nu Skin Enterprises Inc. (NYSE:NUS) today announced it will release fourth quarter and full year 2025 results after the market closes on Thursday, Feb. 12. The Nu Skin management team will host a conference call with the investment community later that same day at 5 p.m. ET. During the call, management will discuss recent results and upcoming business initiatives. The webcast of the conference call, including the financial information presented, will be available on the investor relations page of the company's website at ir.nuskin.com. A replay of the webcast will be available at the same location through Thursday, Feb. 26. About Nu Skin Enterprises Inc. The Nu Skin Enterprises Inc. (

    1/14/26 4:05:00 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    Nu Skin Enterprises to Discuss Company Strategy and Opportunities at ICR Conference

    Nu Skin Enterprises Inc. (NYSE:NUS) today announced president and CEO Ryan Napierski will participate in a moderated fireside chat to discuss company strategy and the state of the business on Monday, Jan. 12. The discussion will include the company's plans in 2026 for launching its Prysm iO intelligent wellness device and future opportunities in emerging markets, including India. The company's fireside chat will be webcast live beginning at 1:30 p.m. ET. Those wishing to access the event can visit the Nu Skin investor relations page at ir.nuskin.com. The archive of the webcast will be available at this same location through Monday, Jan. 26. About Nu Skin Enterprises Inc. The Nu Skin E

    1/9/26 7:00:00 AM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    $NUS
    SEC Filings

    View All

    SEC Form 10-Q filed by Nu Skin Enterprises Inc.

    10-Q - NU SKIN ENTERPRISES, INC. (0001021561) (Filer)

    11/6/25 6:29:08 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    Nu Skin Enterprises Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - NU SKIN ENTERPRISES, INC. (0001021561) (Filer)

    11/6/25 4:26:05 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    SEC Form 144 filed by Nu Skin Enterprises Inc.

    144 - NU SKIN ENTERPRISES, INC. (0001021561) (Subject)

    9/3/25 2:56:58 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    $NUS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Product Officer Hatchett Steven Keith bought $52,855 worth of shares (5,500 units at $9.61), increasing direct ownership by 3% to 167,565 units (SEC Form 4)

    4 - NU SKIN ENTERPRISES, INC. (0001021561) (Issuer)

    11/12/25 4:32:45 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    Chief Product Officer Hatchett Steven Keith bought $49,010 worth of shares (6,500 units at $7.54), increasing direct ownership by 4% to 162,065 units (SEC Form 4)

    4 - NU SKIN ENTERPRISES, INC. (0001021561) (Issuer)

    5/28/25 6:26:44 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    $NUS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Nu Skin downgraded by Jefferies with a new price target

    Jefferies downgraded Nu Skin from Buy to Hold and set a new price target of $39.00 from $43.00 previously

    1/31/23 6:17:27 AM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    DA Davidson reiterated coverage on Nu Skin Enterprises with a new price target

    DA Davidson reiterated coverage of Nu Skin Enterprises with a rating of Neutral and set a new price target of $50.00 from $47.00 previously

    2/17/22 4:46:52 AM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    Citigroup reiterated coverage on Nu Skin Enterprises with a new price target

    Citigroup reiterated coverage of Nu Skin Enterprises with a rating of Neutral and set a new price target of $49.00 from $43.00 previously

    11/24/21 11:03:39 AM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    $NUS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP and General Counsel Clark Chayce David covered exercise/tax liability with 9,049 shares, decreasing direct ownership by 4% to 224,091 units (SEC Form 4)

    4 - NU SKIN ENTERPRISES, INC. (0001021561) (Issuer)

    12/23/25 4:50:21 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    Director Woodbury Edwina D was granted 10 shares, increasing direct ownership by 0.02% to 42,979 units (SEC Form 4)

    4 - NU SKIN ENTERPRISES, INC. (0001021561) (Issuer)

    12/11/25 4:44:37 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    Chief Product Officer Hatchett Steven Keith bought $52,855 worth of shares (5,500 units at $9.61), increasing direct ownership by 3% to 167,565 units (SEC Form 4)

    4 - NU SKIN ENTERPRISES, INC. (0001021561) (Issuer)

    11/12/25 4:32:45 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    $NUS
    Leadership Updates

    Live Leadership Updates

    View All

    Nu Skin Enterprises Appoints James Winett to Board of Directors

    Nu Skin Enterprises (US:NYSE) today announced the appointment of James Winett, a managing member of SIZE Advisory Group, to the company's board of directors. He was elected by shareholders at the annual shareholder meeting for Nu Skin Enterprises. "Jim adds extensive expertise in strategic planning, operations and finance from his many years of consulting experience," said Steven J. Lund, executive chairman of the board. "He will also be an asset to our Rhyz businesses with his background in corporate transactions and advising small businesses and start-ups. We welcome Jim to the board and look forward to tapping into his insights and experience." Winett is a managing member of SIZE Adv

    6/2/25 12:19:00 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    Nu Skin Enterprises Appoints Mark A. Zorko to Board of Directors

    Nu Skin Enterprises (NYSE:NUS) today announced the appointment of Mark A. Zorko, a principal with executive management association Brentwood Advisory Group, to the company's board of directors. The board also appointed Zorko to serve on its audit committee and the nominating and corporate governance committee. "Mark brings extensive C-level leadership experience with several global public companies, as well as more than 20 years of board-level experience," said Steven J. Lund, executive chairman of the board. "We welcome Mark to the board and look forward to leveraging his extensive business insights and experience." Zorko is a principal with Brentwood Advisory, an association he co-found

    9/12/24 4:05:00 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    Palantir Technologies, Dell Technologies, and Erie Indemnity Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

    NEW YORK, Sept. 6, 2024 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, September 23, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P SmallCap 600 are more representative of the small-cap market space. The companies being removed from

    9/6/24 6:43:00 PM ET
    $AAL
    $ADMA
    $ADNT
    Air Freight/Delivery Services
    Consumer Discretionary
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $NUS
    Financials

    Live finance-specific insights

    View All

    Nu Skin Enterprises to Announce Fourth Quarter and Full Year 2025 Financial Results

    Nu Skin Enterprises Inc. (NYSE:NUS) today announced it will release fourth quarter and full year 2025 results after the market closes on Thursday, Feb. 12. The Nu Skin management team will host a conference call with the investment community later that same day at 5 p.m. ET. During the call, management will discuss recent results and upcoming business initiatives. The webcast of the conference call, including the financial information presented, will be available on the investor relations page of the company's website at ir.nuskin.com. A replay of the webcast will be available at the same location through Thursday, Feb. 26. About Nu Skin Enterprises Inc. The Nu Skin Enterprises Inc. (

    1/14/26 4:05:00 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    Nu Skin Enterprises Reports Third Quarter Earnings

    Company preparing for limited introduction of Prysm iO and pre-market opening of India in the fourth quarter Nu Skin Enterprises Inc. (NYSE:NUS) today announced third quarter revenue and earnings per share within its guidance range. Executive Summary Q3 2025 vs. Prior-year Quarter Revenue $364.2 million; (15.3)% or (11.5)% excluding Mavely 2024 revenue (0.4)% FX impact or $(1.7) million Earnings Per Share (EPS) $0.34 compared to $0.17 Customers 746,256; (10)% Paid Affiliates 130,096; (13)% Sales Leaders 31,150; (19)% "We are pleased with our third quarter results, which were in line with expectations, as we continue to navigate a challenging m

    11/6/25 4:06:00 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    Nu Skin Enterprises Announces Quarterly Dividend

    Nu Skin Enterprises, Inc. (NYSE:NUS) today announced its board of directors has declared a quarterly cash dividend of $0.06 per share, which will be paid on Dec. 10, 2025, to shareholders of record on Nov. 28, 2025. About Nu Skin Enterprises Inc. The Nu Skin Enterprises Inc. (NYSE:NUS) family of companies includes Nu Skin and Rhyz Inc. Nu Skin is an intelligent beauty and wellness company, powered by a dynamic affiliate opportunity platform, which operates in nearly 50 markets worldwide. Backed by more than 40 years of scientific research, the company's products help people look, feel and live their best with brands including Nu Skin® personal care, Pharmanex® nutrition and ageLOC® anti-a

    11/6/25 4:05:00 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    $NUS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Nu Skin Enterprises Inc.

    SC 13G/A - NU SKIN ENTERPRISES, INC. (0001021561) (Subject)

    11/12/24 4:47:17 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    Amendment: SEC Form SC 13G/A filed by Nu Skin Enterprises Inc.

    SC 13G/A - NU SKIN ENTERPRISES, INC. (0001021561) (Subject)

    11/6/24 10:20:59 AM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    Amendment: SEC Form SC 13G/A filed by Nu Skin Enterprises Inc.

    SC 13G/A - NU SKIN ENTERPRISES, INC. (0001021561) (Subject)

    11/4/24 10:21:31 AM ET
    $NUS
    Other Pharmaceuticals
    Health Care